Literature DB >> 10247268

Precautions followed by personnel involved with the preparation of parenteral antineoplastic medications.

M P Tortorici.   

Abstract

There have been no guidelines published for precautions to be taken by personnel preparing parenteral antineoplastic agents. A questionnaire was prepared and mailed to all of the Comprehensive Cancer Centers in the United States for their opinions on this subject. A response rate of 84% was achieved. The major concerns of the respondents were 1) the local effect from spillage of antineoplastics on the skin and 2) the possible inhalation of solutions vaporized during preparation. On the basis of the responses to the questionnaire, it is recommended that all hospitals evaluate their procedures for preparing antineoplastics and take appropriate precautions to protect their personnel from any potential adverse effects from the medication prepared.

Mesh:

Substances:

Year:  1980        PMID: 10247268

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  5 in total

Review 1.  The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.

Authors:  G P Kaijser; W J Underberg; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

2.  Comparison of antineoplastic drug handling policies of hospitals with OSHA guidelines: a pilot study.

Authors:  B Valanis; K Driscoll; V McNeil
Journal:  Am J Public Health       Date:  1990-04       Impact factor: 9.308

3.  Occupational handling of cytostatic drugs.

Authors:  B Kolmodin-Hedman; P Hartvig; M Sorsa; K Falck
Journal:  Arch Toxicol       Date:  1983-09       Impact factor: 5.153

4.  Development and operation of a pharmacy-based intravenous cytotoxic reconstitution service.

Authors:  M Anderson; D Brassington; J Bolger
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-01

Review 5.  Handling of cytotoxic drugs by healthcare workers. A review of the risks of exposure.

Authors:  P R Jochimsen
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.